Striving to jumpstart an economy growing at nearly the slowest pace in a decade, India needs Finance Minister Arun Jaitley to deliver a path-breaking Union Budget – a bold statement that is visionary in scope yet granular in its objectives.
While the
Indian economy has shown signs of a revival on the back of favourable global
macroeconomic developments, the GDP growth momentum remains weak as investments
are yet to revive.
For a
government that has come to power on the promise of revolutionizing governance
and pushing the economy towards recovery, this is an opportunity to take some
long pending brave decisions.
Investors
are waiting for the Modi government to articulate second-generation economic
reforms, give a thrust to the creation of world-class infrastructure, usher in
overdue tax, labour and regulatory reforms and unveil business-friendly
policies.
Mr Jaitley’s
last Budget was largely directional, this Budget would have to be about
decisive action and a time-bound roadmap for economic revival.
Expectations
are that the Budget will provide more specifics on Prime Minister Modi’s ‘Make in India’ campaign.
If successful, the PM’s global campaign to encourage investment and
manufacturing in India can transform the country into an equitable and inclusive economic
superpower.
The ‘Make
In India’ Mantra
To translate ‘Make in India’
from a great slogan to an innovative economic growth mantra we need enabling
policies.
First, India
will need to map the areas in which it has a competitive advantage over other popular manufacturing destinations
like China.
At a time when
China is losing its attractiveness as a manufacturing destination because of
rising production costs, India can highlight the fact that the combination of a
strong and stable democratic government, and the relatively free play of market
forces make it a very attractive investment destination. Moreover, nearly
two-thirds of India’s 1.25 billion are in their working age and that makes it
an attractive manufacturing destination in terms of availability and cost of
talent.
There’s a huge
opportunity as an estimated 100 million jobs are expected to move out of China
over the next few years in labour-intensive sectors, according to India's
National Manufacturing Competitiveness Council.
The
economic mess of the past several years has left India’s manufacturing sector
in the doldrums. Urgent action is needed to reverse the damage.
The Budget
therefore needs to spell out policies that will spur domestic manufacturing.
One of the
ways to do it is by offering a weighted premium for indigenously manufactured
products in government tenders. Several countries offer as high as 15-20%
premium for locally-made products as part of their government procurement
policies. In these countries, overseas manufacturers partner with local ones to
avail of these preferential terms. It allows for technology transfers to the
domestic industry which then makes the product and bids for tenders.
Such foreign
collaborations can help Indian manufacturers significantly boost product
quality levels and operational efficiencies, thus improving their
competitiveness in global markets.
Moreover, it
will allow India to strengthen its manufacturing
base, provide employment opportunities to millions and build a self-reliant
nation.
India also
needs to improve the ease of doing business, reduce transaction costs and
expedite approval timelines. It is
unfortunate that India currently ranks a lowly 142nd out of 189 countries in
the World Bank's 'Ease of Business' list.
One of the
steps that can make doing business in the country easier, is the creation of a
special cell within the Prime Minister’s Office (PMO) which will act as a
one-stop shop to address the needs of overseas investors. PM Modi has already
created a special Japan cell for fast-tracking investment proposals and
addressing regulatory and operational impediments. This initiative needs to be
expanded for other important partner countries.
Local investors should
also be given access to a ‘single window’ system for securing all clearances
and approvals from the various central and state agencies. The current inordinately lengthy tiered approval system
should be replaced with self -attestation and time-bound ‘deemed approvals’
Enable a ‘Start-up Culture’
In
order to tap the vast Indian
entrepreneurial energy , the Govt needs to introduce an enabling policy
environment that encourages start-ups.
Special incentives and tax exemptions will lead to movement of ‘ ideas to market’ thus adding momentum to ‘Make in India’
initiative.
Infrastructure Push
To transform India
into a global manufacturing hub, the government will need to improve
infrastructure such as port-to-inland connectivity, cargo airports, uninterrupted
power, adequate potable water, effective effluent treatment facilities and
well-connected roads.
Moreover, the
Special Economic Zones (SEZs) policy needs better implementation if it has to
boost manufacturing and exports. SEZs need to be revived and revitalized.
Simplification of operational norms through self-certification and the removal
of the Minimum Alternate Tax (MAT) are some of the measures that will energize
this ailing sector.
Establishing smart
cities and industrial corridors through high-end road and rail connectivity is
also a key part of this plan.
Addressing India’s Credibility Challenge
The reality is that a ‘Made in
India’ label today comes with huge credibility challenges in terms of quality,
consistency and dependability. We need to build a new national narrative
that corrects the negative global perception of India and highlights the core
strengths and values that differentiate us from other nations.
Fundamental to this is to create
a value proposition for India based on differentiation. We need
to develop a national narrative around knowledge and wisdom that
emanates from our centuries’ old excellence in science and maths.
We
need to create a premium ‘Made in India’ label that
personifies innovation, quality,
reliability and strong IP. Brand India
should stand for ‘Highest Quality at Lowest Cost’.
Strengthening the Pharma Industry
As the largest
and lowest-cost producer of generic drugs in the world, the Indian pharma
industry has a crucial role to play in the government’s ‘Make in India’
initiative.
The Indian pharma industry has earned
the proud label of being the ‘Pharmacy of the World’ by creating a global scale
manufacturing base which has made our
country an indispensable and integral part of global healthcare.
It is
therefore imperative that we build and strengthen this sector so that it can
assume an even greater position in global healthcare. The Budget needs to give
the pharma industry a shot in the arm by ensuring:
a. Support to Capital Investment:
Over the past
decade, the Top 20 Indian pharma companies have invested over Rs 25,000 crores
in setting up global scale manufacturing facilities. These facilities need to
be further augmented through exponential capital investment in the next 10
years. Many of these past investments have been done through
high-interest domestic and overseas borrowings. Foreign currency borrowings
have resulted in huge liabilities on account of sharp Rupee devaluation that
has hurt the balance sheets of several of these companies. Therefore,
low-interest borrowings need to be made available for future investments to be
made by the pharma industry.
b. Incentives to ‘Innovate in India’:
For India to
retain its global leadership, investment in R&D and innovation is
paramount. The 200% weighted tax deduction on R&D costs allowed to pharma
companies does not permit the inclusion of international patenting and overseas
drug development expenses. This tax exemption should be allowed urgently.
c. Rational approach to drug pricing:
The
computation of drug price ceilings should be based on an equitable formula
which ensures like-for-like comparisons and factors the quantum of investments
by pharma companies in creating world-class infrastructure. If pharma companies
are prevented from deriving reasonable return on investments (RoIs), a
draconian pricing policy will erode huge value for this all-important sector
and make business unviable.
d. Incentives for Manufacturing:
Unlike other
sectors, the pharma industry needs international regulatory approvals before it
can export drugs and drug ingredients. The approval process takes an average of
two years, denying all Pharma Units in SEZs the benefit of a tax holiday in
that period. To address this anomaly, pharma SEZs should be allowed to
avail of the tax holiday only after obtaining the required regulatory
approvals. Additionally, the government should also consider the exemption of
duties and taxes on domestic sales of essential drugs from SEZs.
e. Increase in Healthcare Spending:
This Budget
also provides an opportunity for the government to signal its commitment to
universal health coverage. India needs
to urgently raise public healthcare spending to at least 2.5% of GDP from only
about 1% currently. Moreover, it needs to create a highly effective,
sustainable, technology-based universal healthcare system that emphasises individual responsibility for health
supported by enabling state policy.
Conclusion
The prospect of a
reforms-oriented Budget has already started reflecting in market sentiments
with the Sensex hitting record highs.
To live up to
investor expectations the new government needs to introduce enabling policies
as well as build the necessary infrastructure that supports the development
agenda for the country across sectors.
This Budget is a
golden opportunity for the government to usher in the promised “acche din (good times)” which will
attest to the reformist credentials of the Narendra Modi-led government.
Kiran Mazumdar –Shaw, CMD Biocon
No comments:
Post a Comment